Last reviewed · How we verify
DMPA
DMPA, marketed by Fhi 360, is a therapeutic agent with a well-established presence in its primary indication. A key strength of DMPA is its patent protection, which extends until 2028, providing a significant barrier to generic competition. The primary risk facing DMPA is the lack of detailed revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | DMPA |
|---|---|
| Also known as | Depo-Provera, Depot medroxyprogesterone acetate (DMPA), Depot-Medroxyprogestereone Acetate, Depot medroxyprogesterone acetate, Depo Provera |
| Sponsor | Fhi 360 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease (PHASE4)
- Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone (PHASE4)
- Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (PHASE4)
- Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study (PHASE4)
- Injectable Contraception Cohort Study in Punjab, Pakistan
- Kuwa Free! - Live Free! (NA)
- Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (PHASE4)
- Endometrial Biopsy in Progestin Contraceptive Users (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DMPA CI brief — competitive landscape report
- DMPA updates RSS · CI watch RSS
- Fhi 360 portfolio CI